Mesoblast(MESO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

MESO Mesoblast

Not Yet Opened 01-13 16:00:00 EST

17.76

-0.91

-4.87%

盘后17.76

+0.000.00%

18:43 EST

High18.46	Low17.38	Vol417.40K
Open18.46	D1 Closing18.67	Amplitude5.78%
Mkt Cap2.28B	Tradable Cap1.40B	Total Shares128.30M
T/O7.40M	T/O Rate0.53%	Tradable Shares78.65M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"MESO","market":"US","secType":"STK","nameCN":"Mesoblast","latestPrice":17.76,"timestamp":1768338000000,"preClose":18.67,"halted":0,"volume":417404,"hourTrading":{"tag":"盘后","latestPrice":17.76,"preClose":17.76,"latestTime":"18:43 EST","volume":895,"amount":15957.5663,"timestamp":1768347787531},"delay":0,"floatShares":78649063,"shares":128296718,"eps":-0.846,"marketStatus":"Not Yet Opened","change":-0.91,"latestTime":"01-13 16:00:00 EST","open":18.46,"high":18.46,"low":17.38,"amount":7396800.840052,"amplitude":0.057847,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-0.846,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1768381200000},"marketStatusCode":0,"adr":1,"adrRate":10,"listingDate":1447390800000,"exchange":"NASDAQ","adjPreClose":18.67,"preHourTrading":{"tag":"盘前","latestPrice":18.65,"preClose":18.67,"latestTime":"08:04 EST","volume":1013,"amount":18853.582202999998,"timestamp":1768309441863},"postHourTrading":{"tag":"盘后","latestPrice":17.76,"preClose":17.76,"latestTime":"18:43 EST","volume":895,"amount":15957.5663,"timestamp":1768347787531},"volumeRatio":1.426641,"impliedVol":0.8415,"impliedVolPercentile":0.8406},"requestUrl":"/m/hq/s/MESO","defaultTab":"news","newsList":[{"id":"2603652526","title":"Mesoblast Likely to Complete More Ryoncil Therapies than Expected in Fiscal 2026, Says Jefferies","url":"https://stock-news.laohu8.com/highlight/detail?id=2603652526","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603652526?lang=en_us&edition=fundamental","pubTime":"2026-01-14 09:24","pubTimestamp":1768353853,"startTime":"0","endTime":"0","summary":"Mesoblast (ASX:MSB) is likely to complete more patient therapies with Ryoncil than expected in fiscal 2026, according to a Tuesday Jefferies note.It is now expected that 85 patients, up from 78 previo","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7501","BK7508","BK4139","MSB.AU","MESO","BK7067"],"gpt_icon":0},{"id":"2603864501","title":"Mesoblast Issues 6.9 Million New Shares Following Conversion of Unquoted Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2603864501","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603864501?lang=en_us&edition=fundamental","pubTime":"2026-01-13 16:25","pubTimestamp":1768292734,"startTime":"0","endTime":"0","summary":"The latest announcement is out from Mesoblast Limited ( ($AU:MSB) ). Mesoblast Limited has issued 6,856,460 new ordinary fully paid shares followin...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/mesoblast-issues-6-9-million-new-shares-following-conversion-of-unquoted-securities?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/mesoblast-issues-6-9-million-new-shares-following-conversion-of-unquoted-securities?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MESO","BK4139"],"gpt_icon":0},{"id":"2603090185","title":"Mesoblast Seeks ASX Quotation for 7.3 Million New Shares from Employee Scheme","url":"https://stock-news.laohu8.com/highlight/detail?id=2603090185","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603090185?lang=en_us&edition=fundamental","pubTime":"2026-01-13 16:23","pubTimestamp":1768292605,"startTime":"0","endTime":"0","summary":"An update from Mesoblast Limited ( ($AU:MSB) ) is now available. Mesoblast Limited has applied for quotation on the ASX of 7,335,000 new fully paid...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/mesoblast-seeks-asx-quotation-for-7-3-million-new-shares-from-employee-scheme?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/mesoblast-seeks-asx-quotation-for-7-3-million-new-shares-from-employee-scheme?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","MESO"],"gpt_icon":0},{"id":"2602654895","title":"Mesoblast Director Lyn Cobley Increases On-Market Shareholding","url":"https://stock-news.laohu8.com/highlight/detail?id=2602654895","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602654895?lang=en_us&edition=fundamental","pubTime":"2026-01-12 07:48","pubTimestamp":1768175306,"startTime":"0","endTime":"0","summary":"Mesoblast Limited ( ($AU:MSB) ) just unveiled an announcement. Mesoblast has disclosed a change in director Lyn Cobley’s shareholding, with the boa...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/mesoblast-director-lyn-cobley-increases-on-market-shareholding?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/mesoblast-director-lyn-cobley-increases-on-market-shareholding?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","MESO"],"gpt_icon":0},{"id":"2602303321","title":"Mesoblast Stock Rises On Strong Year‑Over‑Year Growth In Ryoncil Sales","url":"https://stock-news.laohu8.com/highlight/detail?id=2602303321","media":"Benzinga_recent_news","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602303321?lang=en_us&edition=fundamental","pubTime":"2026-01-10 01:34","pubTimestamp":1767980040,"startTime":"0","endTime":"0","summary":"Mesoblast reported strong year‑over‑year growth in December quarter sales of its flagship therapy, Ryoncil.","market":"sh","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/01/09/Injecting-Injection-Vaccine-Vaccination-.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/01/09/Injecting-Injection-Vaccine-Vaccination-.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/trading-ideas/movers/26/01/49819234/mesoblast-stock-rises-on-strong-year%e2%80%91over%e2%80%91year-growth-in-ryoncil-sales","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/trading-ideas/movers/26/01/49819234/mesoblast-stock-rises-on-strong-year%e2%80%91over%e2%80%91year-growth-in-ryoncil-sales","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["MESO"],"gpt_icon":0},{"id":"2602319217","title":"Mesoblast Says US Revenue From Sale of Cell Therapy Rises Quarter-on-Quarter in December 2025 Quarter","url":"https://stock-news.laohu8.com/highlight/detail?id=2602319217","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602319217?lang=en_us&edition=fundamental","pubTime":"2026-01-09 07:48","pubTimestamp":1767916097,"startTime":"0","endTime":"0","summary":"Mesoblast  said it earned gross revenue of $35.1 million from the sale of its mesenchymal stromal cell product Ryoncil for the quarter ending Dec. 31, 2025, up 60% from the quarter ending Sept. 30, 2025, according to a Friday filing with the Australian bourse.Ryoncil, the company's US Food and Drug Administration-approved product for the treatment of steroid-refractory acute graft-versus-host disease in children under 12 years of age, was available for purchase in the US from March 2025, an earlier filing showed.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MESO"],"gpt_icon":0},{"id":"2602316319","title":"Mesoblast Boosts Ryoncil Sales 60% and Secures Cheaper US$125m Financing","url":"https://stock-news.laohu8.com/highlight/detail?id=2602316319","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602316319?lang=en_us&edition=fundamental","pubTime":"2026-01-09 07:10","pubTimestamp":1767913806,"startTime":"0","endTime":"0","summary":"Mesoblast Limited ( ($AU:MSB) ) has provided an update. Mesoblast reported gross revenue of US$35.1 million from Ryoncil sales in the quarter ended...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/mesoblast-boosts-ryoncil-sales-60-and-secures-cheaper-us125m-financing?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/mesoblast-boosts-ryoncil-sales-60-and-secures-cheaper-us125m-financing?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MESO"],"gpt_icon":0},{"id":"2602181316","title":"Mesoblast Ltd - Ryoncil Sales for Quarter Increase 60% to US$35.1M","url":"https://stock-news.laohu8.com/highlight/detail?id=2602181316","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602181316?lang=en_us&edition=fundamental","pubTime":"2026-01-09 06:58","pubTimestamp":1767913104,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nFWN3Y90GN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK7501","MSB.AU","BK7508","MESO","BK7067"],"gpt_icon":0},{"id":"2600309590","title":"Mesoblast Says Chair to Retire, Successor Appointed; Shares Up 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2600309590","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600309590?lang=en_us&edition=fundamental","pubTime":"2026-01-02 10:14","pubTimestamp":1767320072,"startTime":"0","endTime":"0","summary":"Mesoblast  said Jane Bell will retire as chair, and its board unanimously appointed Philip Facchina as non-executive chair, according to a Friday Australian bourse filing.Bell will remain on the board as a non-executive director, the filing said.The biotechnology company's shares rose almost 3% in recent trading on Friday.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MSB.AU","BK7501","BK7508","BK4139","MESO","BK7067"],"gpt_icon":0},{"id":"2600037688","title":"BRIEF-Mesoblast Appoints Philip Facchina As Non-Executive Chair","url":"https://stock-news.laohu8.com/highlight/detail?id=2600037688","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600037688?lang=en_us&edition=fundamental","pubTime":"2026-01-02 09:20","pubTimestamp":1767316836,"startTime":"0","endTime":"0","summary":"BRIEF-Mesoblast Appoints Philip Facchina As Non-Executive ChairJan 2  - Mesoblast Ltd MSB.AX:MESOBLAST ANNOUNCES CHANGES TO BOARD OF DIRECTOR ROLESPHILIP FACCHINA APPOINTED AS NON-EXECUTIVE CHAIRJANE BELL RETIRES AS CHAIRFurther company coverage: MSB.AX ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260102:nTUE9FP4WP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7501","BK7508","BK4139","MESO","MSB.AU","BK7067"],"gpt_icon":0},{"id":"2600034377","title":"Press Release: Mesoblast Announces Changes to Board of Directors' Leadership Roles","url":"https://stock-news.laohu8.com/highlight/detail?id=2600034377","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600034377?lang=en_us&edition=fundamental","pubTime":"2026-01-02 07:02","pubTimestamp":1767308520,"startTime":"0","endTime":"0","summary":"NEW YORK, Jan. 01, 2026  -- Mesoblast Limited , global leader in allogeneic cellular medicines for inflammatory diseases, today announced that as foreshadowed at the recent Annual General Meeting the Board will undertake a number of changes in line with the Company's evolution to a revenue-generating commercial company.Having presided during the most transformational period for the company with its first U.S. Food & Drug Administration  approval and successful product commercialization, Ms Jane Bell will retire from her role as Chair and will remain on the Board as a non-executive director. The Board has unanimously appointed Mr Philip Facchina to the role of non-executive Chair and Ms Lyn Cobley as Chair of the Audit and Risk Committee. Mr William Burns remains as Mesoblast Vice-Chair and Chair of the Nomination and Remuneration Committee.Mr Facchina joined the Mesoblast board in March 2021 and has over forty years of experience in corporate strategy, finance, and business development","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["R","BK7067","BK4150","MSB.AU","MSB","MESO","BK4575","BK4232","MSC","BK4006","BK4022","BK7508","BK7501","BK4139"],"gpt_icon":0},{"id":"2600310560","title":"Mesoblast Ltd - Philip Facchina Appointed as Non-Executive Chair","url":"https://stock-news.laohu8.com/highlight/detail?id=2600310560","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600310560?lang=en_us&edition=fundamental","pubTime":"2026-01-02 06:38","pubTimestamp":1767307110,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260101:nTUE9FP4WP:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","BK4139","BK7508","BK7501","MESO","MSB.AU"],"gpt_icon":0},{"id":"2600031055","title":"Mesoblast Ltd - Jane Bell Retires as Chair","url":"https://stock-news.laohu8.com/highlight/detail?id=2600031055","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600031055?lang=en_us&edition=fundamental","pubTime":"2026-01-02 06:38","pubTimestamp":1767307110,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260101:nTUE9FP4WP:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","MSB.AU","BK7501","BK4139","MESO","BK7508"],"gpt_icon":0},{"id":"2595768897","title":"Mesoblast Ltd Files for Offering of Upto $250 Mln Ads Representing Ordinary Shares - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2595768897","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595768897?lang=en_us&edition=fundamental","pubTime":"2025-12-31 19:30","pubTimestamp":1767180612,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251231:nFWN3Y103D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7067","BK7501","BK4139","MSB.AU","MESO"],"gpt_icon":0},{"id":"2595769466","title":"Mesoblast to Release 10.2 Million Shares From Voluntary Escrow","url":"https://stock-news.laohu8.com/highlight/detail?id=2595769466","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595769466?lang=en_us&edition=fundamental","pubTime":"2025-12-30 14:06","pubTimestamp":1767074805,"startTime":"0","endTime":"0","summary":"Mesoblast (ASX:MSB) said that 10.2 million of its shares will be released from voluntary escrow on Jan. 8, 2026, in accordance with the Australian Securities Exchange's listing rule 3.10A, according to a Tuesday Australian bourse filing.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","MESO","BK7501","BK7067","XJO.AU","BK7508","XAO.AU","XKO.AU","MSB.AU"],"gpt_icon":0},{"id":"2595759386","title":"Press Release: Mesoblast Retires Senior Debt with Non-Dilutive, Lower Cost, Five-Year Credit Line","url":"https://stock-news.laohu8.com/highlight/detail?id=2595759386","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595759386?lang=en_us&edition=fundamental","pubTime":"2025-12-30 07:57","pubTimestamp":1767052620,"startTime":"0","endTime":"0","summary":"Mesoblast has option to draw down up to US$125 million by June 30, 2026. New facility does not encumber any of Mesoblast's material assets or intellectual property. The new credit-line has a fixed interest rate of 8.00% per annum, a substantial reduction from Mesoblast's current debt facilities, with a five-year interest only period. The initial US$75 million drawn is unsecured until the remainder of the NovaQuest debt is repaid, no later than July 8, 2026, after which the entire new facility  will be secured solely with the Temcell royalty.Mesoblast's Ryoncil  for the treatment of steroid-refractory acute graft versus host disease  in pediatric patients 2 months and older is the first FDA-approved mesenchymal stromal cell  therapy. Please see the full Prescribing Information at www.ryo","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4150","MSB.AU","MSB","BK4006","BK4575","BK7501","MSC","BK4022","BK4232","MESO","BK7508","BK4139","R","BK7067"],"gpt_icon":0},{"id":"2595756078","title":"Mesoblast Repays Existing Senior Loans From Shareholder's New Five-Year Facility; Shares Rise 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2595756078","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595756078?lang=en_us&edition=fundamental","pubTime":"2025-12-30 07:44","pubTimestamp":1767051874,"startTime":"0","endTime":"0","summary":"Mesoblast  repaid its existing senior secured loan from Oaktree Capital Management in full and its royalty facility from NovaQuest Capital Management in part, according to a Tuesday filing with the Australian bourse.The repayment followed a $75 million withdrawal from a new five-year facility of up to $125 million provided by a shareholder, carrying a fixed interest rate of 8% per annum, the filing said.The company has an option to withdraw up to $50 million until June 30, 2026, the filing said.The shareholder will receive warrants to purchase about 323,00 American Depositary Shares  at $21.51 per ADS, the filing added.The facility can be repaid without incurring early payment or make-whole fees, the company said.Shares of the company rose 3% in recent Tuesday trade.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","BK7501","BK7508","BK4139","MESO","ADS.AU","MSB.AU","BK7016"],"gpt_icon":0},{"id":"2592791957","title":"Has Mesoblast’s Surging Share Price Left Its Future Growth Prospects Underappreciated?","url":"https://stock-news.laohu8.com/highlight/detail?id=2592791957","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592791957?lang=en_us&edition=fundamental","pubTime":"2025-12-17 09:16","pubTimestamp":1765934210,"startTime":"0","endTime":"0","summary":"If you are wondering whether Mesoblast is a hidden bargain or a value trap at its current share price, you are not alone. This breakdown aims to unpack that question.\nThe stock has been choppy in the short term, down 1.8% over the last week. That comes after a 24.8% jump over the past month and a 42.8% gain over the last year, all against a still negative year to date return of 17.3% and a 215.8% rise over three years.\nRecent moves have been driven less by day to day noise and more by...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/has-mesoblasts-surging-share-price-left-its-future-growth-pr","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/has-mesoblasts-surging-share-price-left-its-future-growth-pr","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","BK7501","BK7067","DCF","BK7508","MSB.AU","MESO"],"gpt_icon":0},{"id":"2590526802","title":"Mesoblast Says Drug Candidate for Treatment of Severe Acute Graft Versus Host Disease Shows Superior Outcomes Than Ruxolitinib","url":"https://stock-news.laohu8.com/highlight/detail?id=2590526802","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590526802?lang=en_us&edition=fundamental","pubTime":"2025-12-12 10:06","pubTimestamp":1765505219,"startTime":"0","endTime":"0","summary":"Mesoblast  said drug candidate Ryoncil  showed superior outcomes in complete and overall remission in a comparison study with ruxolitinib for treatment of steroid-refractory acute graft versus host disease, following an independent, peer-reviewed comparative study, according to a Friday filing with the Australian bourse.Shares of the company rose 2% in recent Friday trade.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4585","MESO","BK4218","BK7508","BK4139","BK7067","BK4181","BK4588","MSB.AU","SPN","HST","BK7501"],"gpt_icon":0},{"id":"2590547736","title":"Independent Study Presented at American Society of Hematology (ASH) Annual Meeting Concludes Remestemcel-L Superior to Ruxolitinib in Clinical Outcomes as Treatment for SR-aGvHD","url":"https://stock-news.laohu8.com/highlight/detail?id=2590547736","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590547736?lang=en_us&edition=fundamental","pubTime":"2025-12-12 07:22","pubTimestamp":1765495320,"startTime":"0","endTime":"0","summary":"NEW YORK, Dec.  11, 2025  (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that an independent pe","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/11/3204384/0/en/Independent-Study-Presented-at-American-Society-of-Hematology-ASH-Annual-Meeting-Concludes-Remestemcel-L-Superior-to-Ruxolitinib-in-Clinical-Outcomes-as-Treatment-for-SR-aGvHD.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4006","MSC","BK4107","ASH","LU2463526074.USD","BK4117","SPN","BK4575","BK4109","MSB","BK4139","MESO","AFG","SR","BK4150","BK4197"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.mesoblast.com","stockEarnings":[{"period":"1week","weight":-0.0436},{"period":"1month","weight":-0.0172},{"period":"3month","weight":-0.0106},{"period":"6month","weight":0.4392},{"period":"1year","weight":0.0338},{"period":"ytd","weight":-0.0155}],"compareEarnings":[{"period":"1week","weight":0.0028},{"period":"1month","weight":0.0176},{"period":"3month","weight":0.043},{"period":"6month","weight":0.1047},{"period":"1year","weight":0.1933},{"period":"ytd","weight":0.0174}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, the United Kingdom, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. The company has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. Mesoblast Limited was incorporated in 2004 and is headquartered in Melbourne, Australia.","yearOnYearQuotes":[{"month":1,"riseRate":0.545455,"avgChangeRate":0.007317},{"month":2,"riseRate":0.5,"avgChangeRate":0.041084},{"month":3,"riseRate":0.5,"avgChangeRate":0.16594},{"month":4,"riseRate":0.4,"avgChangeRate":0.169294},{"month":5,"riseRate":0.5,"avgChangeRate":-0.027677},{"month":6,"riseRate":0.3,"avgChangeRate":-0.077641},{"month":7,"riseRate":0.6,"avgChangeRate":0.120859},{"month":8,"riseRate":0.2,"avgChangeRate":-0.055117},{"month":9,"riseRate":0.4,"avgChangeRate":0.04193},{"month":10,"riseRate":0.5,"avgChangeRate":-0.049086},{"month":11,"riseRate":0.8,"avgChangeRate":0.095285},{"month":12,"riseRate":0.545455,"avgChangeRate":0.005342}],"exchange":"NASDAQ","name":"Mesoblast","nameEN":"Mesoblast"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Mesoblast(MESO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Mesoblast(MESO) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Mesoblast,MESO,Mesoblast股票,Mesoblast股票老虎,Mesoblast股票老虎国际,Mesoblast行情,Mesoblast股票行情,Mesoblast股价,Mesoblast股市,Mesoblast股票价格,Mesoblast股票交易,Mesoblast股票购买,Mesoblast股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Mesoblast(MESO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Mesoblast(MESO) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction